Fonte
UNAIDS
Autoria
UNAIDS
Resumo
UNAIDS welcomes additional evidence released in May 2015 that early initiation of antiretroviral therapy has a positive effect on the health and well-being of people living with HIV. The United States National Institutes of Health-funded international randomized clinical trial START (Strategic Timing of Antiretroviral Treatment) has found compelling evidence that the benefits of starting antiretroviral therapy as soon as someone is diagnosed outweigh the risks of delaying until their CD4 count has fallen to 350 cells/mm3.1. These findings reaffirm the goal of making quality HIV treatment available to all people living with HIV. Earlier provision of HIV treatment can mean both better health outcomes for people living with HIV and simplification of treatment services. Availability of earlier treatment can encourage more people to learn their HIV status, offering opportunities to provide expanded access to HIV prevention services along with treatment. Scale-up of earlier HIV treatment also implies increased global resource needs and additional strains on already overburdened public and community health systems. Realizing the promise of the START results will require governments, donors, civil society and other stakeholders to systematically address the implementation, financing and other challenges ahead.
2015 UNAIDS IMPLICATIONS OF THE START STUDY DATA
Link para download aqui